Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.

Zhang RH, Wang S, Luo RH, Zhou M, Zhang H, Xu GB, Zhao YL, Li YJ, Wang YL, Yan G, Liao SG, Zheng YT, Li R.

Bioorg Med Chem Lett. 2019 Dec 15;29(24):126638. doi: 10.1016/j.bmcl.2019.126638. Epub 2019 Aug 28.

PMID:
31685340
2.

Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists.

Zhou M, Luo RH, Hou XY, Wang RR, Yan GY, Chen H, Zhang RH, Shi JY, Zheng YT, Li R, Wei YQ.

Eur J Med Chem. 2017 Mar 31;129:310-324. doi: 10.1016/j.ejmech.2017.01.010. Epub 2017 Jan 12.

PMID:
28235704
3.

Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.

Ali A, Wang J, Nathans RS, Cao H, Sharova N, Stevenson M, Rana TM.

ChemMedChem. 2012 Jul;7(7):1217-29. doi: 10.1002/cmdc.201200079. Epub 2012 May 3.

4.

Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.

Ao Z, Yu Z, Wang L, Zheng Y, Yao X.

PLoS One. 2008 Apr 16;3(4):e1995. doi: 10.1371/journal.pone.0001995.

5.

Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra V, Rajendran KS, Buhrlage SJ, Mankowski MK, Rasmussen L, White EL, Ptak RG, Gabuzda D.

J Biol Chem. 2015 Apr 17;290(16):10504-17. doi: 10.1074/jbc.M114.626903. Epub 2015 Feb 27.

6.

HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.

Wang Y, Kinlock BL, Shao Q, Turner TM, Liu B.

Retrovirology. 2014 Oct 11;11:89. doi: 10.1186/s12977-014-0089-5.

7.

Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.

Huang W, Zuo T, Jin H, Liu Z, Yang Z, Yu X, Zhang L, Zhang L.

Mol Divers. 2013 May;17(2):221-43. doi: 10.1007/s11030-013-9424-3. Epub 2013 Feb 3.

PMID:
23378232
8.

HIV-1 Escape from Small-Molecule Antagonism of Vif.

Sharkey M, Sharova N, Mohammed I, Huff SE, Kummetha IR, Singh G, Rana TM, Stevenson M.

MBio. 2019 Feb 26;10(1). pii: e00144-19. doi: 10.1128/mBio.00144-19.

9.

Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Zuo T, Liu D, Lv W, Wang X, Wang J, Lv M, Huang W, Wu J, Zhang H, Jin H, Zhang L, Kong W, Yu X.

J Virol. 2012 May;86(10):5497-507. doi: 10.1128/JVI.06957-11. Epub 2012 Feb 29.

10.

Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors.

Pu C, Luo RH, Zhang M, Hou X, Yan G, Luo J, Zheng YT, Li R.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):4150-4155. doi: 10.1016/j.bmcl.2017.07.026. Epub 2017 Jul 10.

PMID:
28754362
12.

Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.

Pery E, Rajendran KS, Brazier AJ, Gabuzda D.

J Virol. 2009 Mar;83(5):2374-81. doi: 10.1128/JVI.01898-08. Epub 2008 Dec 24.

13.

Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.

Walker RC Jr, Khan MA, Kao S, Goila-Gaur R, Miyagi E, Strebel K.

J Virol. 2010 May;84(10):5201-11. doi: 10.1128/JVI.02318-09. Epub 2010 Mar 10.

14.

Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.

Ribeiro AC, Maia e Silva A, Santa-Marta M, Pombo A, Moniz-Pereira J, Goncalves J, Barahona I.

J Virol. 2005 Jan;79(2):823-33.

15.

Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.

Britan-Rosich E, Nowarski R, Kotler M.

J Mol Biol. 2011 Jul 29;410(5):1065-76. doi: 10.1016/j.jmb.2011.03.058.

16.

Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein.

Pan T, He X, Chen B, Chen H, Geng G, Luo H, Zhang H, Bai C.

Eur J Med Chem. 2015 May 5;95:500-13. doi: 10.1016/j.ejmech.2015.03.050. Epub 2015 Mar 21.

PMID:
25847768
17.

Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.

Sugiyama R, Abe M, Nishitsuji H, Murakami Y, Takeuchi H, Takaku H.

Antiviral Res. 2013 Sep;99(3):307-11. doi: 10.1016/j.antiviral.2013.06.017. Epub 2013 Jul 4.

PMID:
23831493
18.
19.

Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.

Zhang S, Zhong L, Chen B, Pan T, Zhang X, Liang L, Li Q, Zhang Z, Chen H, Zhou J, Luo H, Zhang H, Bai C.

Antiviral Res. 2015 Oct;122:20-7. doi: 10.1016/j.antiviral.2015.07.009. Epub 2015 Aug 1.

PMID:
26241003
20.

Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.

Sinha C, Nischal A, Pant KK, Bandaru S, Nayarisseri A, Khattri S.

Bioinformation. 2014 Oct 30;10(10):611-6. doi: 10.6026/97320630010611. eCollection 2014.

Supplemental Content

Support Center